Use of surfactant beyond respiratory distress syndrome, what is the evidence?

Area of Science:

• Neonatal Medicine
• Pulmonology
• Pharmacology

Background:

• Surfactant replacement therapy is FDA-approved for premature infants with respiratory distress syndrome (RDS) due to surfactant deficiency.
• Established benefits include reduced mortality and air leak syndromes in premature infants with RDS.
• Off-label surfactant use is explored for various respiratory failures beyond classic RDS.

Purpose of the Study:

• To review current evidence on off-label surfactant therapy in neonatal respiratory failure.
• To explore surfactant use in term infants with conditions like meconium aspiration syndrome (MAS), pneumonia/sepsis, and congenital diaphragmatic hernia.
• To examine surfactant use in premature infants beyond 72 hours for acute respiratory failure and surfactant lavage.

Main Methods:

• Literature review of current evidence on off-label surfactant therapy.
• Analysis of studies investigating surfactant use in term infants with specific lung diseases.
• Evaluation of research on extended use in premature infants and surfactant lavage techniques.

Main Results:

• Evidence supports surfactant's efficacy in specific off-label neonatal respiratory conditions.
• The review highlights ongoing research into surfactant's role in drug delivery and deficiency evaluation.
• Off-label applications show potential benefits in managing complex neonatal respiratory issues.

Conclusions:

• Surfactant replacement therapy has expanding applications beyond its approved indications.
• Further investigation is warranted to establish definitive guidelines for off-label surfactant use.
• Surfactant holds potential for novel therapeutic strategies, including drug delivery and diagnosing surfactant deficiency.